Published 1 year ago

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Summary by Ground News

CytomX to receive $35 million upfront payment with the potential for additional research, milestone, and royalty payments. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing. CytomX's Probody technology enables proteins to be activated locally in diseased tissue.

0 Articles

All

Left

Center

Right

WTVB

Moderna, CytomX announce mRNA collaboration

(Reuters) - Moderna Inc on Thursday said it will collaborate with CytomX Therapeutics for the development of certain investigational messenger RNA-based therapies. (Reporting by Bhanvi Satija in Bengaluru; Editing by Devika Syamnath)

1 year ago

Read Full Article

Globe Newswire

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Collaboration will combine Moderna’s mRNA technology with CytomX’s Probody® Platform to generate and develop therapeutics for oncology and non-oncology...

1 year ago

Read Full Article

Green Stock News

Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Green Stock News for the New Green Economy.

1 year ago

Read Full Article

modernatx.com

Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million upfront payment with the potential for additional research, milestone, and royalty payments CAMBRIDGE, MA and SOUTH SAN FRANCISCO, CA / ACCESSWIRE / January 5, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) thera

1 year ago

Read Full Article

pharmiweb.com

MODERNA AND CYTOMX ANNOUNCE STRATEGIC RESEARCH COLLABORATION FOR MRNA-BASED CONDITIONALLY ACTIVATED THERAPEUTICS

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced a collaboration and licensing agreement to create investigational ...

1 year ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center1Last Updated1 year agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

0 Articles

0 Articles

Moderna, CytomX announce mRNA collaboration

Moderna, CytomX announce mRNA collaboration

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

MODERNA AND CYTOMX ANNOUNCE STRATEGIC RESEARCH COLLABORATION FOR MRNA-BASED CONDITIONALLY ACTIVATED THERAPEUTICS

MODERNA AND CYTOMX ANNOUNCE STRATEGIC RESEARCH COLLABORATION FOR MRNA-BASED CONDITIONALLY ACTIVATED THERAPEUTICS

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics